Key management & founders

Prof. Pablo V. Escribá, PhD.

Founder & CEO

Professor of Cell Biology at the UIB. Director of the Molecular and Cellular Biomedicine research group. Main promoter and founder of Lipopharma, pioneer in the discovery of membrane-lipid therapy (MLT) and inventor of several MLT-based drugs. He has held senior research stages in USA (New York, Kansas City and Charleston), Switzerland (Geneve) and Hungary (Szeged).

Antonio J. González, BSc.

Managing Director

Mr. González holds a Degree in Business Administration and is responsible for financial management, accounting and general administration since 2010. Before joining Lipopharma Mr Gonzalez accumulated more than 25 years of experience in top financial, accounting and general administration positions in medium and large companies in the logistics (Seur) and international commerce (Central Mimbrera) space, among others

Daniel Bermejo, MSc.

Clinical Research manager

Daniel has a Degree in Biology and a Master’s in research by the University of Nottingham, UK. Over the last 12 years he has hold different professional positions in the field of Clinical Research, including Clinical Project Manager at Fina Biotech (10 years), Pharma Mar or Ely Lilly.

Catalina Ana Rossello, PhD

Head of Scientific Area: Clinical R&D projects

Dr. Rossello holds a degree in Biology (UIB), a degree in Biochemistry (UIB) and a PhD in in Molecular Biology (Autonomous University of Madrid). After a postdoctoral fellow research position at Lund University (Sweden) and a senior research position at the UIB (with a European FP7 Marie Curie grant), she joined Lipopharma as senior research scientist (with a Felip Bauçà contract from the local Government) first and then as head of the clinical R&D scientific area. She is liaison with all other scientific areas to ensure the flow of laboratory discoveries to clinical development.

Victoria Llado, PhD.

Head of Lipopharma’s research Laboratory

Dr. Llado holds a degree in Biology (UIB) and a degree in Biochemistry (UIB) and a PhD in in Molecular Biology (UIB). After postdoctoral fellow research positions at the Gastro-Intestinal Unit of MGH, Harvard Medical School (Boston, MA, USA) at the Sanford-Burnham Medical Research Institute (San Diego, CA, USA) and at the UIB (with a grant from the Asociación Española Contra el Cancer, AECC), she joined Lipopharma as head of the laboratory facilities in December 2018.

Paula Fernandez, PhD

Head of Oncology Research & Biomarker discovery

Dr. Fernandez has a degree in Biochemistry (University of Oviedo) and a PhD in Biochemistry and Molecular Biology (University of Oviedo). After a brief period in the Biomedicine Laboratory directed by Dr. Pablo V. Escriba and Dr. Xavier Busquets (UIB), she joined Lipopharma in November 2013, after obtaining a Torres Quevedo contract. Her research is developed mainly in the fields of proteomics and molecular biology. She is leading the basic and applied research aimed at further elucidating 2OHOA’s mechanism of action in oncology and at the identification and development of biomarkers to support the clinical development of 2OHOA. She is the principal investigator of several scientific projects, including CLINGLIO, a 6.15M€ H2020 R&D Grant to fund a PIIB trial with 2OHOA for the treatment of glioblastoma.

Manuel Torres, PhD

Head of CNS research

Dr. Torres has a degree in Pharmacy and a Master in Physiology and Neuroscience (University of Seville). He earned his PhD in biomedical sciences working in a research project in the field of Alzheimer’s pathophysiology. With 10-years expertise in this field (five years as a PhD student and five more years as a senior scientist) and research stages at Sanofi-Aventis Research Centre (Paris, France) and the Catholic University of Leuven/VIB Center for Human Genetics (Leuven, Belgium), he has published several scientific articles in the fields of pathophysiology and pharmacology of neurodegenerative disorders. He joined the scientific team of Lipopharma in 2013.


Key External Consultants


Antoine Perier, DEA (Consultant)

Clinical Trial Methodology & Process Expert

Antoine has more than 25 years of experience in supporting bio-pharmaceutical companies in their general and clinical development to ensure financial and scientific optimization, and regulatory compliance. With a degree in Biology and a Master of Research (DEA) in Reproductive Biology – Endocrinology, he has held operational and executive responsibilities at Sanofi, AnalyticA, Cardinal Systems (clinical CRO where he served as CEO for 18 years) and Crane Solutions.

Elena Berengena, MSc (Consultant)

Clinical Project Manager

Elena has Pharmacy Degree, and a master’s degree in clinical trials, with over 10 years of experience in clinical research working within Clinical Research & Development and Operations teams for the conduction of clinical trials in Oncology and inflammatory diseases.

Richard J. Taylor, PhD (Consultant)

Medical and Regulatory affairs

Dr. Taylor has been a consultant to Lipopharma since 2011 being responsible for key regulatory documents (IB, IMPD, IND) and involvement with formal regulatory interactions with the European Medicines Agency (EMA) relating to the Scientific Advice/Protocol Assistance process, UK Regulatory Agency (MHRA) and US (FDA) for CTA and IND submissions respectively on behalf of Lipopharma. He was awarded a Medical Research Council (MRC) Scholarship from the Institute of Psychiatry (UK) and has a PhD in neuroscience in the field of neurodegenerative movement disorders and regularly consults in this and many other areas of drug development and medical affairs. Richard has extensive multi-national pharmaceutical company experience as Head of International Clinical and Regulatory Affairs, Zeneca Pharmaceuticals (now AstraZeneca), Medical Information/Pharmacovigilance Manager with Fisons Pharmaceuticals (now part of Aventis), and Head OTC Medicines at The Wellcome Research Laboratories (part of Glaxo SmithKline). He is currently Executive Director at The Medical & Regulatory Partnership Ltd (TMRP), a drug development consultancy specializing in regulatory professional services.



© 2019 Lipopharma Therapeutics. All rights reserved | legal notice

Ctra. de Valldemossa Km. 7,4. ParcBIT. Edifici Disset. 2n. Mod. C-8. E07121 - Palma de Mallorca. Spain  | Phone/Fax: +34 971439886  |  Email:

Login Form